Streamex (STEX) AI Stock Analysis

• Market Cap: $176.50M
• Dividend Yield: N/A
• Average Volume (3M): 833.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: -66.67%
• EPS Growth: 3.34%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Asset Management
• EPS (TTM): -0.14
• Shares Outstanding: 40,068,027
• 10 Day Avg. Volume: 777,871
• 30 Day Avg. Volume: 833,981
• PEG Ratio: 0.11
• Price to Book (P/B): -61.18
• Price to Sales (P/S): 2201.04
• P/FCF Ratio: -18.50
• Enterprise Value/Market Cap: 0.05
• Enterprise Value/Revenue: 689.59
• Enterprise Value/Gross Profit: -4.42
• Enterprise Value/Ebitda: -0.22
• 1Y Price Target: $12.00
• Price Target Upside: 172.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.25
• Revenue Forecast (FY): N/A

• Rating: 34 Underperform
• Price Target: ―

BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.

Streamex Business Overview & Revenue Model

Company Description

BioSig Technologies, Inc. is a medical technology company that operates in the healthcare sector, focusing on advanced signal processing solutions for the medical industry. The company's core product is the PURE EP System, an innovative platform designed to improve the clarity and precision of cardiac signal data during electrophysiology (EP) procedures. This technology aims to enhance the diagnosis and treatment of complex arrhythmias by providing physicians with clearer, more interpretable data, potentially improving patient outcomes.

How the Company Makes Money

BioSig Technologies generates revenue primarily through the sale and lease of its PURE EP System to hospitals and medical institutions. The company also earns money by providing ongoing support services, including maintenance and upgrades, to ensure optimal performance of its systems. Additionally, BioSig may enter into strategic partnerships and collaborations with other healthcare entities and technology providers to expand its market reach and enhance its technological offerings. Key revenue streams include direct sales, leasing agreements, and service contracts associated with the PURE EP System.

Streamex Financial Statement Overview

Summary

BioSig Technologies is facing significant financial challenges. The income statement shows persistent losses and declining revenue, while the balance sheet reflects high leverage and negative equity. Cash flow statements highlight ongoing cash burn, raising concerns about the company's ability to sustain operations without significant financial restructuring or external funding.

Income Statement

BioSig Technologies has consistently reported negative net income with a declining trend in revenue over the past years, leading to poor profitability metrics. The gross profit margin is negative, and the net profit margin has worsened substantially. This indicates significant challenges in generating revenue and managing costs effectively.

Balance Sheet

The company's balance sheet reveals high leverage with negative stockholders' equity, resulting in a negative equity ratio. The debt-to-equity ratio cannot be calculated due to negative equity, but the high level of liabilities relative to assets suggests financial instability and a potential risk of insolvency.

Cash Flow

The cash flow analysis shows negative operating and free cash flow, indicating a consistent cash burn. Although financing activities have been able to cover some of the cash outflows, the lack of positive free cash flow growth is concerning and poses a sustainability risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.00K	40.00K	18.00K	286.00K	441.00K	0.00
Gross Profit	-2.03M	40.00K	18.00K	229.00K	242.00K	-550.00K
EBITDA	-40.79M	-12.42M	-28.15M	-26.97M	-33.21M	-58.59M
Net Income	-39.87M	-10.33M	-29.04M	-27.05M	-31.92M	-52.22M
Balance Sheet
Total Assets	130.51M	842.00K	1.80M	4.11M	15.52M	30.39M
Cash, Cash Equivalents and Short-Term Investments	11.04M	155.00K	293.00K	458.00K	11.66M	28.27M
Total Debt	0.00	102.00K	452.00K	765.00K	656.00K	314.00K
Total Liabilities	137.34M	2.26M	4.68M	3.71M	2.95M	5.11M
Stockholders Equity	-6.85M	-1.44M	-2.91M	418.00K	12.35M	24.48M
Cash Flow
Free Cash Flow	-7.89M	-4.76M	-17.50M	-21.87M	-26.94M	-26.69M
Operating Cash Flow	-7.89M	-4.76M	-17.31M	-21.70M	-26.40M	-26.60M
Investing Cash Flow	221.00K	0.00	-186.00K	-168.00K	-542.00K	-87.00K
Financing Cash Flow	18.10M	4.71M	17.33M	10.57M	10.33M	42.85M

Streamex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STEX, the sentiment is Positive. The current price of 4.4 is above the 20-day moving average (MA) of 4.25, below the 50-day MA of 5.00, and above the 200-day MA of 3.94, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 50.00 is Neutral, neither overbought nor oversold. The STOCH value of 71.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STEX.

Streamex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SWKH	79 Outperform	$203.33M	9.03	8.45%	―	2.70%	100.41%
SAMG	65 Neutral	$168.16M	19.32	9.23%	5.73%	4.18%	-9.53%
EARN	60 Neutral	―	10.42	9.66%	17.71%	630.98%	234.98%
TPVG	59 Neutral	$257.35M	7.57	9.43%	17.74%	206.13%	298.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SSSS	45 Neutral	$234.34M	5.05	35.45%	5.45%	―	―
STEX	34 Underperform	$176.50M	―	―	―	-66.67%	3.34%